Network meta-analysis of 6 trials (n=989) in hereditary transthyretin amyloidosis with polyneuropathy: vutrisiran (SMD −1.66) and patisiran (SMD −1.56) improved mNIS+7 most vs placebo; no SAE differences. Very low to moderate certainty; hypothesis-generating.
Meta-analysisn = 989
Duarte et al. Pharmacological Interventions for Hereditary Transthyretin-Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta-Analysis